[Skip to Content]
[Skip to Content Landing]
Citations 0
February 9, 2011

KRAS Genotypes and Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab

JAMA. 2011;305(6):564-566. doi:10.1001/jama.2011.87

To the Editor: The study by Dr De Roock and colleagues1 suggests that all KRAS mutations in patients with metastatic colorectal cancer are not the same and that they interact differently with anti-epidermal growth factor receptor monoclonal antibodies. Did the authors analyze, in cancers harboring the p.G13D mutation, the mutational status of BRAF and other genetic elements that determine the activity of anti-epidermal growth factor receptor monoclonal antibodies in such tumors that are not mutated for KRAS?2

First Page Preview View Large
First page PDF preview
First page PDF preview